Abstract
Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate in Manchester, UK, was detected in 1999. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p
Original language | English |
---|---|
Pages (from-to) | 1068-1076 |
Number of pages | 8 |
Journal | Emerging infectious diseases |
Volume | 15 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2009 |
Fingerprint
Dive into the research topics of 'Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure'. Together they form a unique fingerprint.Impacts
-
Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery
David Denning (Participant), Peter Warn (Participant), Michael Bromley (Participant), Paul Bowyer (Participant) & Caroline Moore (Participant)
Impact: Health and wellbeing, Policy, Economic
-
Diagnostics and novel life-saving therapies for aspergillosis
David Denning (Participant), Michael J. Anderson (Participant), Caroline Moore (Participant), Peter Warn (Participant), Paul Bowyer (Participant), Michael Bromley (Participant), Nicola Smith (Participant), Susan Howard (Participant) & Robert Niven (Participant)
Impact: Health impacts